All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group

Ex-Merck unit Poxel seeks IPO to finalise diabetes drug

Poxel, a French pharmaceuticals company that was spun out of Merck Serono in 2009, has filed a document de base for an IPO.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree